TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00595426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Oral
Study: NCT03648333

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exforge tab. 10/160mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lodivixx tab. 5/160mg
Study: NCT03372499

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: diet management strategy for encephalopathy
Description: diet management strategy for encephalopathy means diet management strategy from the nutritional management consensus of hepatic encephalopathy.
Study: NCT00263081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate and current lipid-lowering treatment
Description: Cohort 1: Weight is less than 50 kg:~Lapaquistat acetate 50 mg, tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks.~Cohort 2: Weight is more than 50 kg:~Lapaquistat acetate 100 mg, tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Current lipid-lowering treatment
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks.
Study: NCT03725787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CuroCell S.A.M. ® pro mattress
Description: During 30 days, participants will use the static air mattress.
Study: NCT03286413

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: microwave ablation
Description: Microwave ablation and cryoablation are both thermal ablation techniques for minimally invasive treatment of breast tumor. They are performed percutaneously by ultrasound guidance.The tumor can be completely killed without injurying adjacent tissue.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microwave ablation
Description: Microwave ablation and cryoablation are both thermal ablation techniques for minimally invasive treatment of breast tumor. They are performed percutaneously by ultrasound guidance.The tumor can be completely killed without injurying adjacent tissue.
Study: NCT03294161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immucillin DI4G
Description: Immucillin DI4G was administered by topical use at 2% concentration once a day for 20 days associated with Meglumine antimoniate administered by intravenous route at a dosage of 20mg/kg/day, during 20 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meglumine antimoniate
Description: Placebo for topical use once a day at the ulcer for 20 days associated with Meglumine antimoniate administered as the standard treatment for cutaneous leishmaniasis by intravenous route at a dosage of 20mg/kg/day, during 20 days.
Study: NCT01203774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine insulin
Description: 20-180 units per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine insulin
Description: 20-180 units per day
Study: NCT04313283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents Taking Action
Description: A peer-led intervention, Parents Taking Action is the psychoeducational and child behavior management intervention led by trained Parent Leaders.
Study: NCT02517359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV6153 single dose
Description: Safety and tolerability of single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV6153 matching placebo single dose
Description: Safety and tolerability of single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV6153 14 day repeat dose
Description: Safety and tolerability of repeat doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV6153 14 day repeat dose
Description: Safety and tolerability of repeat doses
Study: NCT00987974

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin 7 days
Description: atorvastatin 80 mg/day for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo 7 days
Description: placebo 7 days
Study: NCT03753165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval exercise
Description: High intensity interval exercise at 80% of the maximal heart rate derived from the maximal graded exercise. Each individual will undergo 12 sessions of HIIE over a period of six weeks
Study: NCT00785369

Intervention type: DEVICE
Group type: OTHER
Intervention: Reflectance confocal microscopy
Description: Reflectance confocal microscopy (VivaScope 1500)
Study: NCT03776513

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: an MRI examination
Description: The MRI examination implies the realization of an emotional associative memory task

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: an MRI examination
Description: The MRI examination implies the realization of an emotional associative memory task
Study: NCT00949351

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aliskiren 300mg/d
Description: Aliskiren 300mg/d v.s. placebo for 12wk
Study: NCT02859857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXQ-350
Description: BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes. When both the components are assembled together stable SapC-DOPS nanovesicles are formed(clinical formulation BXQ-350).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXQ-350
Description: BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes. When both the components are assembled together stable SapC-DOPS nanovesicles are formed(clinical formulation BXQ-350).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXQ-350
Description: BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes. When both the components are assembled together stable SapC-DOPS nanovesicles are formed(clinical formulation BXQ-350).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXQ-350
Description: BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes. When both the components are assembled together stable SapC-DOPS nanovesicles are formed(clinical formulation BXQ-350).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXQ-350
Description: BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes. When both the components are assembled together stable SapC-DOPS nanovesicles are formed(clinical formulation BXQ-350).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXQ-350
Description: BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes. When both the components are assembled together stable SapC-DOPS nanovesicles are formed(clinical formulation BXQ-350).
Study: NCT02791724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Desiconnect
Description: Desiconnect is an Internet intervention for persons with epilepsy and elevated depression. Content is continuously adapted to patients' concerns and needs. Techniques to overcome depression (e.g., cognitive restructuring, behavioral activation) and to cope with anxiety symptoms (e.g., exposure, role of avoidance, mindfulness exercises) are conveyed in interactive sequences that are accompanied by audio recordings, illustrations, and worksheets. Topics covered also include coping with epilepsy symptoms, identifying and coping with seizure auras and triggers, and the role of nutrition and exercise. Patients are also prompted to regularly complete brief symptom severity self-monitoring questionnaires. Optional daily text messages with motivational content accompany the program. The program can be accessed for 180 days after registration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAU
Description: Care as Usual

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAU
Description: Care as Usual
Study: NCT00092131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Montelukast
Description: Montelukast 10 mg tablet administered orally as a single witnessed dose before exercise challenge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Montelukast
Description: Montelukast 10 mg tablet administered orally as a single witnessed dose before exercise challenge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo tablet administered orally as a single witnessed dose before exercise challenge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo tablet administered orally as a single witnessed dose before exercise challenge
Study: NCT02512575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9567 Monohydrat
Description: AZD9567 oral suspension 0.5 to 10 mg/ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral suspension/ Placebo capsule
Description: Matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 60mg oral capsules (12 capsules of 5 mg each).
Study: NCT04060394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase I and Phase II: LAE001/prednisone + afuresertib
Description: In the Phase I portion of the study will identify the RPD2 of the combined therapy. In the Phase II will evaluate LAE001/prednisone + afuresertib at the RP2D (Cohort 1) and docetaxel/prednisone + afuresertib (Cohort 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase I and Phase II: LAE001/prednisone + afuresertib
Description: In the Phase I portion of the study will identify the RPD2 of the combined therapy. In the Phase II will evaluate LAE001/prednisone + afuresertib at the RP2D (Cohort 1) and docetaxel/prednisone + afuresertib (Cohort 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase I and Phase II: LAE001/prednisone + afuresertib
Description: In the Phase I portion of the study will identify the RPD2 of the combined therapy. In the Phase II will evaluate LAE001/prednisone + afuresertib at the RP2D (Cohort 1) and docetaxel/prednisone + afuresertib (Cohort 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase I and Phase II: LAE001/prednisone + afuresertib
Description: In the Phase I portion of the study will identify the RPD2 of the combined therapy. In the Phase II will evaluate LAE001/prednisone + afuresertib at the RP2D (Cohort 1) and docetaxel/prednisone + afuresertib (Cohort 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase I and Phase II: LAE001/prednisone + afuresertib
Description: In the Phase I portion of the study will identify the RPD2 of the combined therapy. In the Phase II will evaluate LAE001/prednisone + afuresertib at the RP2D (Cohort 1) and docetaxel/prednisone + afuresertib (Cohort 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase I and Phase II: LAE001/prednisone + afuresertib
Description: In the Phase I portion of the study will identify the RPD2 of the combined therapy. In the Phase II will evaluate LAE001/prednisone + afuresertib at the RP2D (Cohort 1) and docetaxel/prednisone + afuresertib (Cohort 2).
Study: NCT03664700

Intervention type: DEVICE
Intervention: LMA Protector
Description: The LMA Protector will be inserted when a supraglottic device is needed
Study: NCT03757299

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HPV Test
Description: Vaginal specimens for HPV test will be collected by participants themselves using flocked swabs after explanations by co-investigators. Two transport mediums will be used for those self-collected vaginal samples: NaCl 0.9%.
Study: NCT03173950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants will receive nivolumab at standard dose of 240 mg IV every 2 weeks for cycles 1 through 2, then doses of 480 mg every 4 weeks for a total of 14 additional doses
Study: NCT03737955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Receive IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03500874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FUDR
Description: Floxuridine(FUDR) 0.12 mg/kg/day，on Day 1-14 through the HAI pump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 180 mg/m2 IV over 90 minutes on Day 1, 15.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 180 mg/m2 IV over 90 minutes on Day 1, 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin 200mg/m2 ivd over 2 hours on Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Leucovorin 200mg/m2 ivd over 2 hours on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU
Description: 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5FU
Description: 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 180mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan 180mg/m2
Study: NCT03960190

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using Eureka Breast Pump with Expression Kit
Description: Each subject will undergo two expression sessions for single and double electric pumping in randomized order to reduce the variation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using Eureka Breast Pump with Expression Kit
Description: Each subject will undergo two expression sessions for single and double electric pumping in randomized order to reduce the variation.
Study: NCT03325712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 705564
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 705564
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 705564
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 705564
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 705564
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 705564
Description: Film-coated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Solution for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Solution for injection
Study: NCT03360253

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. reuteri DSM 17938 in drops
Description: L. reuteri DSM 17938 will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. reuteri DSM 17938 in drops
Description: L. reuteri DSM 17938 will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consists of an identical formulation except that the L. reuteri is not present

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consists of an identical formulation except that the L. reuteri is not present
Study: NCT00017381

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo PBSCT
Study: NCT00308009

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TVT and Prolapse surgery
Description: 1. TVT at the time of Prolapse surgery~2. TVT 3 months after Prolapse Surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TVT and Prolapse surgery
Description: 1. TVT at the time of Prolapse surgery~2. TVT 3 months after Prolapse Surgery
Study: NCT01268488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ninja 2 Investigational Blood Glucose Meter
Description: Untrained subjects with diabetes performed Blood Glucose(BG) tests from the subject's capillary blood obtained from fingerstick, palm, and forearm using the Ninja 2 investigational meter. All BG results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
Study: NCT00942799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genz-644282 (28-day dosing schedule)
Description: Genz-644282 will be administered as a 60-minute IV infusion. The initial dose of Genz-644282 will be 0.5 mg/m2 and will be administered once weekly for 3 consecutive weeks on Day 1, Day 8, and Day 15 of the 28 day cycle. Each 28-day period will represent one treatment cycle. Study drug will continue to be given until disease progression or unacceptable toxicity is observed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genz-644282 (21-day dosing schedule)
Description: The starting dose of Genz-644282 for the 21-day schedule will be prescriptive and will be based on review of available safety data from the 28-day dosing schedule by the Investigator and Sponsor. Patients will receive Genz-644282 once-weekly for 2 consecutive weeks on Day 1 and Day 8 of a 21 day cycle. Each 21-day period will represent 1 treatment cycle. Patients enrolled in subsequent cohorts will receive higher doses until the MTD is established.
Study: NCT01706393

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics (six probiotic cultures)
Description: Effects of probiotics supplementation on intestinal microbiome; 2capsule bid orally for six weeks, 1capsule(500mg) Started eating probiotics one week prior of radiation therapy.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.
Study: NCT01481701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m² / 14days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: oxaliplatin
Study: NCT03013725

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02683317

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: docosahexaenoic acid
Description: Docosahexaenoic acid is a dietary supplement derived from algae.

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: sunflower oil
Description: Sunflower similar to the excipient used in experimental group
Study: NCT00834483

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knotless suture for wound closure
Description: Angiotech Quill SRS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Layered traditional wound closure (monocryl)
Description: Layered traditional wound closure (monocryl)
Study: NCT00301015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid diagnostic test for malaria
Description: We used Paracheck Pf® (Orchid Biomedical Systems, India) as rapid diagnostic test in this trial

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rapid diagnostic test for malaria
Description: We used Paracheck Pf® (Orchid Biomedical Systems, India) as rapid diagnostic test in this trial
Study: NCT02042625

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nasopharyngeal
Study: NCT02849509

Intervention type: DRUG
Intervention: Pradaxa (dabigatran)
Description: Pradaxa (dabigatran etexilate)110mg or 150mg

Intervention type: DRUG
Intervention: Vitamin K antagonist
Description: Vitamin K antagonist or Pradaxa
Study: NCT00629161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicinal Mixture (composed of Roucongrong and adjuvant)
Description: 12 months period of Traditional Chinese Medicinal Mixture per day plus 1 month wash-out period without herbal medicine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 12 months period of placebo plus 1 month period without placebo